Showing 1701-1710 of 2657 results for "".
- Clots, Strokes And Rashes. Is COVID-19 A Disease Of The Blood Vessels?https://modernod.com/news/clots-strokes-and-rashes-is-covid-19-a-disease-of-the-blood-vessels/2478497/Whether it’s strange rashes on the toes or blood clots in the brain, the widespread ravages of COVID-19 have increasingly led researchers to focus on how the novel coronavirus sabotages the body’s blood vessels, according to an NPR
- Sanofi Enters $3.7-Billion Deal to Buy Principia Biopharmahttps://modernod.com/news/sanofi-enters-3-7-billion-deal-to-buy-principia-biopharma/2478166/Sanofi announced Monday a definitive agreement to acquire all of Principia Biopharma’s outstanding stock for $100 per share in cash, representing an equity value of around $3.7 billion, boosting the French drugmaker’s core research areas of autoimmune and allergic diseases. The deal,
- AstraZeneca to Supply Europe Up to 400 Million COVID-19 Vaccine Doseshttps://modernod.com/news/astrazeneca-to-supply-europe-up-to-400-million-covid-19-vaccine-doses/2479514/AstraZeneca announced that it has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA) to supply up to 400 million doses of the University of Oxford’s COVID-19 experimental vaccine, with deliveries starting by the end of this year. CEO Pascal Soriot remarked that ̶
- WHO Suspends Hydroxychloroquine Arm in Global COVID-19 Trial Amid Safety Reviewhttps://modernod.com/news/who-suspends-hydroxychloroquine-arm-in-global-covid-19-trial-amid-safety-review/2477821/The World Health Organization (WHO) has implemented a temporary pause of the hydroxychloroquine arm within the agency’s Solidarity Trial in COVID-19 patients pending a review of safety data by the study’s Data Safety M
- AbbVie, Allergan Gain US Antitrust Clearance for Dealhttps://modernod.com/news/abbvie-allergan-gain-us-antitrust-clearance-for-deal/2477714/The US Federal Trade Commission (FTC) accepted the proposed consent order in connection with AbbVie’s pending $63-billion acquisition of Allergan, the companies announced. The FTC’s decision means that all required antitrust clearances needed for the merger have now been obtained.
- AbbVie-Allergan Deal Foes Try Again to Spur an FTC Crackdownhttps://modernod.com/news/abbvie-allergan-deal-foes-try-again-to-spur-an-ftc-crackdown/2477311/AbbVie and Allergan’s megamerger is likely in the final stages of review after the pair agreed to offload three drugs, including IL-23 hopeful brazikumab. But a cadre of union and consumer groups say that’s not enough—and they’re taking another stab at turning regulators against
- Mark McGrath to Headline Celebration at Optometry’s Meeting 2020https://modernod.com/news/mark-mcgrath-to-headline-celebration-at-optometrys-meeting-2020/2477126/The American Optometric Association has announced that it is celebrating the decade of the 90s at its annual Optometry’s Meeting, June 24-28, in National Harbor, Maryland/Washington, D.C. “Mark McGrath’s ’90s Experience” will headline the closing Celebration o
- Optina Diagnostics and Wagner Macula Retina Center to Conduct a Study to Identify the Causes of Memory Loss Through Eye Diagnosticshttps://modernod.com/news/optina-diagnostics-and-wagner-macula-retina-center-will-collaborate-to-conduct-a-clinical-study-to-identify-the-causes-of-memory-loss-through-eye-diagnostics/2477076/Optina Diagnostics and Wagner Macula Retina Center are entering into a collaboration agreement to conduct a clinical study for the advancement of Optina’s Retinal Deep Phenotyping platform. This collaboration will lay the groundwork for Optina’s future pivotal clinical trial. &
- New Scientific And Clinical Analyses Regarding Bausch + Lomb Surgical And Pharmaceutical Products To Be Presented ARVOhttps://modernod.com/news/new-scientific-and-clinical-analyses-regarding-bausch-lomb-surgical-and-pharmaceutical-products-to-be-presented-during-the-association-for-research-in-vision-and-ophthalmology-meeting/2476505/Bausch + Lomb announced that researchers will present the results of nine new scientific and clinical analyses involving the company’s pharmaceutical and surgical products, as well as data from the company’s Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillanc
- Proxy Advisory Firms Back Allergan in Battle with Dissident Shareholder Appaloosahttps://modernod.com/news/proxy-advisory-firms-back-allergan-in-battle-with-dissident-shareholder-appaloosa/2476472/Allergan said Monday that proxy advisory firms Institutional Shareholder Services (ISS) and Glass Lewis have recommended that shareholders vote for all of the board’s proposals at its annual meeting on May 1, and against hedge fund Appaloosa’s proposal calling for the immediate separa